MEIRAGTX HOLDINGS PLC

Insightful look at MeiraGTx’s insider sale—how CEO Alexandria’s rule‑based trade reflects broader gene‑therapy market trends, reimbursement dynamics, and tech adoption for investor strategy.

Perceptive Advisors’ latest 555k‑share purchase of MeiraGTx (10.8m total, 1.16% stake) signals confidence in its gene‑therapy platform; watch regulatory milestones and warrant upside for future growth.

MeiraGTx insider sales reveal a 16% stake drop, hinting at possible confidence shifts amid volatile stock prices.

MeiraGTx insider moves show routine vesting, not panic—execs buying while covering taxes, hinting steady confidence in its gene‑therapy pipeline.